Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential
Kenjiro Aogi(Hiroshima University), Toshiwo Andoh(Soka University), Ryungsa Kim(Hiroshima Institute of Technology), Naoki Hirabayashi(Hiroshima University), Toshihisa Kusano(Hiroshima Bunkyo University), Yasuhiro Fujiwara(Yokohama City University), Hidetaka Sumiyoshi(Hiroshima University), Akiko Mizutani, Michio Yamakido(Hiroshima University), Masahiko Nishiyama(Hiroshima University), Tetsuya Toge(Hiroshima University), Kosuke Okada(Iwate University)
International Journal of Cancer
July 17, 1997
Cited by 16
Related Papers
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
Cancer immunoediting from immune surveillance to immune escape
|Immunology|2007|1k
An antitumor promoter from Moringa oleifera Lam.
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|1999|404
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
|Cancer Science|2019|375
Current status of the molecular mechanisms of anticancer drug-induced apoptosis
|Cancer Chemotherapy and Pharmacology|2002|255